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Core evidence clinical impact summary for lumiracoxib in osteoarthritis
Outcome measure Evidence Implications
Patient-oriented evidence
Reduced pain intensity Clear Effective relief of pain intensity, comparable with celecoxib, rofecoxib, diclofenac,
naproxen, and ibuprofen
Improvement in joint stiffness Clear Improvement in joint stiffness (WOMAC score) comparable with celecoxib and
diclofenac
Improved quality of life Clear Improvement in ability to perform daily activities (WOMAC score) comparable 
with celecoxib and diclofenac. Improvement in physical functioning and mental
health (SF-36) compared with placebo 
Tolerability Clear Minor GI adverse events are frequent (e.g. dyspepsia, diarrhea, and nausea) and
occur at a similar incidence with celecoxib, diclofenac, ibuprofen, and naproxen
Low incidence of GI ulcers Substantial Lower risk of upper GI ulcer complications compared with ibuprofen or naproxen 
in nonaspirin population only
Changes in liver function Substantial No clinically relevant elevations in ALT/AST levels were reported at the indicated 
dose of lumiracoxib (100 mg) although isolated cases of liver-related adverse events
have been reported at this dose. AST/ALT elevations may occur at higher doses 
(400 mg). Lumiracoxib should not be used in patients with, or at risk of, liver
disease, and liver function should be monitored.
Reduced risk of hypertension Limited Lower risk of de-novo hypertension with lumiracoxib than naproxen. Reduced SBP
and DBP with lumiracoxib compared with naproxen/ibuprofen 
Low risk of CV events Moderate (limited in
patients at high risk)
Lumiracoxib has a similar CV risk profile as ibuprofen, and a similar CV profile 
as naproxen in patients taking aspirin. Lumiracoxib has an increased risk of CV
events compared with naproxen in patients not taking aspirin
continued overleaf...
Abstract
Introduction: The symptoms of osteoarthritis (OA) include joint pain, stiffness, and a reduced ability to perform normal daily activities,
which result in decreased quality of life. There is currently no known cure or means of preventing the progression of joint damage due
to OA. Therefore, treatment focuses on the control of symptoms, including the use of various agents [including nonselective and
selective nonsteroidal antiinflammatory drugs (NSAIDs)] to provide pain relief and reduce inflammation. Lumiracoxib is a selective
cyclooxygenase-2 (COX-2) inhibitor for the treatment of OA.
Aims: To review the evidence for the treatment of OA with lumiracoxib.
Evidence review: There is evidence that lumiracoxib reduces the pain and stiffness associated with OA, and is as effective as
nonselective NSAIDs, and the COX-2 inhibitor celecoxib. There is some evidence that lumiracoxib treatment results in a lower incidence
of upper gastrointestinal (GI) ulcer complications compared with nonselective NSAIDs. However, evidence suggests that there is no GI
benefit in patients receiving concomitant aspirin medication. With the exception of GI ulcers, the evidence indicates that lumiracoxib has
a tolerability profile similar to nonselective NSAIDs: low risk of cardiovascular (CV) events and a low incidence of edema. Changes in
liver function occur in some patients, largely at doses >100 mg. The cost effectiveness of lumiracoxib compared with nonselective
NSAIDs remains to be determined. 
Clinical value: Lumiracoxib is an alternative treatment option for OA which provides effective pain relief without the GI complications
associated with nonselective NSAIDs, and with a low risk of CV events. Lumiracoxib is contraindicated in patients with current,
previous, or at risk of, hepatic impairment.
Core Evidence. 2007;2(2):131–150.
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Osteoarthritis (OA) is one of the most prevalent forms of arthritis.
There is currently no known cure or means of preventing OA.
Therefore, treatment focuses on the control of symptoms,
including the use of the nonselective nonsteroidal
antiinflammatory drugs (NSAIDs) and selective cyclooxygenase-2
(COX-2) inhibitors. The COX-2 inhibitors were developed with the
aim of providing pain relief with less gastrointestinal (GI) adverse
effects than the NSAIDs. In recent years, there have been
concerns regarding the cardiovascular (CV) safety of COX-2
inhibitors, and there is a need for newer agents that demonstrate
a clinical benefit in a greater proportion of OA patients compared
with the risk of a CV event. Lumiracoxib (Prexige®, COX-189;
Novartis) is an orally active selective COX-2 inhibitor developed
for the treatment of OA, rheumatoid arthritis (RA), and acute pain.
The objective of this article is to review the evidence base for the
clinical use and CV risk–benefit profile of lumiracoxib in the
management of patients with OA. The use of lumiracoxib in acute
pain is excluded.
Methods
English language medical literature databases were searched 
for relevant evidence related to the treatment of OA with
lumiracoxib. The searches were conducted in December 2005
using the search terms “lumiracoxib OR Prexige.” The cut-off date
was from the beginning of the database to the date of the search
unless otherwise stated. 
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fgci
• EMBASE, http://datastarweb.com
• BIOSIS, http://datastarweb.com
• Database of Abstracts of Reviews of Effects (DARE),
http://www.york.ac.uk/inst/crd/darehp.htm
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index0.htm
• Public Library of Science, http://clinicaltrials.plosjournals.org/
• Clinical Evidence (BMJ), http://www.clinicalevidence.com
• http://www.clinicaltrials.gov
• http://www.clinicalstudyresults.org. Search strategy “Novartis
AND lumiracoxib”
• National Institute for Health and Clinical Excellence (NICE),
http://www.nice.org.uk
• National Guideline Clearinghouse, http://www.guideline.gov.
Search strategy “osteoarthritis”
After removal of duplicates, a total of 235 records were identified.
Clinical guidelines for OA were also identified from NICE, the
American College of Rheumatology (ACR), and the European
League Against Rheumatism (EULAR). Records were manually
reviewed and any animal studies, in-vitro studies, news articles,
nonsystematic reviews, editorials, articles that mentioned
lumiracoxib but did not discuss clinical trial data, duplicated data
presented in previous publications, pharmacokinetic and interaction
studies which were not directly relevant to the review, and studies
with lumiracoxib in indications other than OA were excluded.
Eighteen papers remained and were included in the evidence base
(Table 1). Two systematic reviews were identified. All other articles
were of level 2 evidence reported as full publications.
Online abstracts from the following congresses were also
searched in December, 2005 using the search terms “lumiracoxib
OR Prexige”:
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Category Number of records
Full papers Abstracts
Initial search 235 32
records excluded 217 28
records included 18 4
Search updates, new records 13 0
records excluded 7 0
records included 6 0
Level 1 clinical evidence
(systematic review, meta analysis)
61
Level 2 clinical evidence (RCT) 12 3
Level ≥3 clinical evidence
trials other than RCT 0 0
case reports 0 0
pharmacokinetic studies 6 0
Economic evidence 0 0
Total records included 24 4
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review
...table continued
Outcome measure Evidence Implications
Low incidence of edema Substantial Incidence similar to that with celecoxib, diclofenac, naproxen, and ibuprofen
Economic evidence
Cost effectiveness No evidence Evidence required to determine whether clinical effectiveness translates into 
an economic benefit compared with other treatments for OA
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CV, cardiovascular; DBP, diastolic blood pressure; GI, gastrointestinal; OA, osteoarthritis; SBP, systolic blood pressure; 
SF, Short Form; WOMAC, Western Ontario and McMaster Universities OA Index.133
• ACR, all conferences from 2002 to 2005,
http://www.rheumatology.org/annual/abstracts/search.asp 
• EULAR, all conferences from 2004 to 2005,
http://www.abstracts2view.com/eular/ 
• Osteoarthritis Research Society International (OARSI) 9th World
Congress, December 2–5, 2004,
http://www.oarsi.org/04Abstracts/Final_OARSI04_Abstracts.pdf 
A total of 32 abstracts were identified (Table 1). Twenty-eight
abstracts were excluded because they were animal studies (n=3),
in-vitro studies (n=1), were in indications other than OA (n=3),
were nonrelevant pharmacokinetic/pharmacodynamic studies
(n=2), did not cite data (n=1), or were abstracts that duplicated
results from OA studies which have since been published in full
(n=18). One abstract was level 1 evidence (pooled analysis), and
all other abstracts were of level 2 evidence. 
PubMed searches were updated on January 27, 2006 and again
on May 14, 2007. A total of 13 new records were identified, of
which seven were excluded for the following reasons:  in-vivo
study (n=1), animal study (n=1), review article (n=5). Six articles
remained, and were included (Table 1). 
Disease overview
OA is the most common form of arthritis, which gradually
damages the cartilage lining the joints (and the underlying bone)
primarily in the hands, knees, hips, and spine. The four main risk
factors for OA are age, family history, obesity, and joint trauma
(WHO 2003). It is estimated that symptomatic OA affects 9.6% of
men and 18% of women aged ≥60 years worldwide, and is more
prevalent in Europe and the US than in other parts of the world
(Woolf & Pfleger 2003). Of the 115.9 million US adults aged 
≥35 years, 24.3 million (21%) have OA (Singh et al. 2002).
Globally, approximately 40% of individuals over 70 years of age
suffer from OA of the knee (WHO 2003). 
The prevalence of OA is expected to increase due to the increasing
proportion of the elderly in the population (Reginster 2002), and it
is expected to be the fourth leading cause of disability by 2020
(Woolf & Pfleger 2003). The increasing burden of musculoskeletal
disorders, such as OA, has been recognized by the United Nations
and the World Health Organization (WHO), which has endorsed the
Bone and Joint Decade 2000–2010 initiative, with the aim of
increasing awareness of these conditions (Woolf & Pfleger 2003).
The symptoms of OA include joint pain, stiffness, and a reduced
ability to perform normal daily activities, which result in a
decreased quality of life. Approximately 80% of patients with OA
have limitation of movement and 25% cannot perform their major
daily activities (WHO 2003). Indeed, musculoskeletal conditions
such as OA have been associated with a poorer quality of life than
CV, chronic respiratory, and GI conditions (Reginster 2002).
Economic burden of OA
In the US alone, of the $US214.9 billion in total costs for
musculoskeletal disorders in 1995, $US82.4 billion was associated
with various forms of arthritis (the most prevalent being OA 
and RA) (WHO 2003). In addition, the economic burden of
musculoskeletal disorders in Canada has been reported to be close
to that of cancer (Badley 1995). 
The direct and indirect costs of OA place a considerable burden both
on the individual and society. A Canadian study estimating the direct
and indirect arthritis-attributable costs to individuals with disabling 
hip and/or knee OA demonstrated that 80% of costs incurred were 
for time lost from employment and leisure by the patient and unpaid
informal caregivers. Costs increased with worsening health status 
and greater OA severity (Gupta et al. 2005). In addition, a European
retrospective study in patients with OA of the knee reported that
direct costs over a period of 12 months (2000–2001) were €934/
patient per year (including €146 on therapy, of which 42% was spent
on drugs), and indirect costs were €1236/patient per year 
(31% due to loss of productivity of patients and 60% due to informal
care provided by primary caregivers) (Leardini et al. 2004). 
Pathophysiology of OA
Prostaglandins cause the swelling and pain associated with OA
(Mitchell & Warner 1999). The cyclooxygenase enzymes play a key
role in the production of prostaglandins by converting arachidonic
acid to prostaglandin H2 (PGH2), which is then metabolized by
specific isomerases to tissue-specific prostanoids [e.g. PGI2
(prostacyclin) and TXA2 (thromboxane)] (Fig. 1). To date, two
isoforms of the cycloxoygenase enzyme, COX-1 and COX-2, have
been identified. COX-1 is produced constitutively in several tissues
including the GI tract, endothelial cells, kidney, and platelets,
whereas COX-2 is expressed constitutively in some tissues 
(e.g. kidney) and is also inducible (Dubois et al. 1998; Warner &
Lumiracoxib | clinical impact review
Core Evidence 2007;2(2)
Arachidonic acid
NSAID (-) COX-2 inhibitor (-)
NSAID (-)
PGH2
COX-1       COX-2
PGI2 TXA2 PGD2 PGE2 PGF2
Endothelium,
kidney,
platelets, 
brain
Platelets,
vascular,
smooth-muscle
cells,
macrophages,
kidney
Mast cells,
brain, 
airways
Brain, kidney,
vascular
smooth-muscle
cells, platelets
Uterus, 
airways,
vascular
smooth-muscle
cells, eye
Fig. 1 | The cyclooxygenase pathway (reproduced with
permission from Fitzgerald & Patrono 2001). Arachidonic
acid is converted by cyclooxygenase (COX)-1 and 
COX-2 to the intermediate prostaglandin H2 (PGH2).
PGH2 is converted by tissue-specific isomerases to
multiple prostanoids; prostacyclin (PGI2), thromboxane
A2 (TXA2), prostaglandin D2 (PGD2), prostaglandin E2
(PGE2), and prostaglandin F2 (PGF2). These prostanoids
exert prominent effects via cell-membrane receptorsMitchell 2004). Through its production of gastroprotective
prostaglandin E2 (PGE2), the constituent COX-1 enzyme is
recognized as being protective of the GI system. Cytokines and
growth factors increase the expression of COX-2 at inflammatory
sites. Therefore, the COX-2 enzyme primarily mediates pain and
inflammation (Warner & Mitchell 2004).
Current therapy options
Currently, there is no known cure for OA or means of preventing it.
The main goals of OA management are to control pain and to
improve function and quality of life, while avoiding adverse side
effects. Pharmacologic treatments for OA include: analgesics such
as acetaminophen (paracetamol), which relieve pain but do not
reduce inflammation; NSAIDs, which are both analgesic and
antiinflammatory; injectable corticosteroids; and symptomatic 
slow-acting drugs for OA such as glucosamine sulfate, chondroitin
sulfate, and hyaluronic acid. Nonpharmacologic treatments such as
patient education, diet, exercise, and the use of insoles may also
improve the symptoms of OA. Surgical treatment (i.e. prosthetic joint
replacement) is generally only used when there is significant joint
damage and all other treatment options have failed.
NSAIDs relieve pain and inflammation by blocking the action of 
the COX-2 enzyme. There are currently two types of NSAIDs:
nonselective NSAIDs suppress both the COX-1 and COX-2
enzymes to varying degrees; COX-2 inhibitors (i.e. selective NSAIDs)
suppress the COX-2 enzyme only (Fitzgerald & Patrono 2001).
Nonselective NSAIDs
Nonselective NSAIDs such as naproxen, ibuprofen, diclofenac,
and nabumetone, have been available on the market for many
years. A major disadvantage of nonselective NSAIDs is their
potential to cause GI side effects by inhibition of COX-1 and
topical toxicity (Lazzaroni & Porro 2004). For example,
nonselective NSAIDs increase the risk of serious ulcer
complications (bleeding, perforation, obstruction), hospitalization,
surgery, and death (Singh et al. 1997; Wolfe et al. 1999). In the
1980s, GI complications caused by nonselective NSAID use was
estimated to cause approximately 16 000 deaths and 100 000
hospitalizations each year in the US alone. 
Risk factors for NSAID-associated upper GI complications include
use of multiple NSAIDs (e.g. NSAID and aspirin), high doses of
NSAIDs, prior ulcer complications, advanced age, and concomitant
corticosteroid or anticoagulant use (Scheiman & Fendrick 2005).
Approximately 50% of patients who regularly take nonselective
NSAIDs have gastric erosions, and 15–30% have ulcers when
examined by endoscopy. Clinical upper GI events may occur in
3–4.5% of patients taking NSAIDs, and serious complicated
events develop in approximately 1.5% (Laine 2001). These GI
adverse events often lead to discontinuation of treatment, and
may have an important impact on the patient’s quality of life and
healthcare costs. Therefore, the human and economic costs of
these complications could be reduced by using medications
which reduce their incidence.
In order to reduce the incidence of GI complications
nonselective NSAIDs may be used in combination with
gastroprotective agents such as misprosotol, H2 receptor
antagonists, and proton pump inhibitors (PPIs), which add to the
total cost of therapy. But patient compliance to misprosotol is
limited by its side effects (e.g. diarrhea and abdominal cramps),
and H2 receptor antagonists do not offer significant protection
against gastric ulcers (Singh & Triadafilopoulos 2005). In
comparison to these other treatments PPIs are better tolerated.
Eradication of Helicobacter pylori intestinal infection has also
been shown to reduce peptic ulcer incidence in patients
receiving NSAIDs. However, it was less effective at preventing
NSAID-associated ulcers than treatment with a PPI (Vergara et
al. 2005). Evidence suggests that H. pylori infection and NSAID
use are independent risk factors for GI complications (Huang et
al. 2002). 
COX-1 also plays a role in the synthesis of prostanoids which
regulate renal function. It is well established that nonselective
NSAIDs have adverse effects on the kidney, and may cause
peripheral edema and hypertension (Gambaro & Perazella
2003). Data from two meta analyses have shown that
nonselective NSAIDs increase blood pressure (BP), although the
effect varied depending upon the NSAID used (Pope et al. 1993;
Johnson et al. 1994). In addition, two prospective studies have
recently reported conflicting data regarding the increased risk of
hypertension with the use of nonselective NSAIDs. A study in
women demonstrated an increased risk of hypertension with
high daily doses of acetaminophen and ibuprofen (Forman et al.
2005). In contrast, a study in men did not demonstrate an
increased risk with these drugs (Kurth et al. 2005).
There is limited evidence that nonselective NSAIDs are
associated with an increased risk of CV events. Data from an
observational study of 367 general practices in the UK between
2000 and 2004 has suggested that the use of diclofenac and
ibuprofen is associated with an increased risk of myocardial
infarction (MI) (Hippisley-Cox & Coupland 2005).
Selective COX-2 inhibitors
The COX-2 inhibitors are a new generation of NSAIDs. These
drugs were developed to selectively inhibit the COX-2 enzyme
with the aim of stopping the production of inflammatory
prostaglandins without inhibiting the production of
prostaglandins that protect the stomach and intestine.
Therefore, these selective COX-2 inhibitors were proposed to
provide comparable efficacy to that of nonselective NSAIDs, but
with a lower incidence of GI adverse effects. Several COX-2
inhibitors have been developed for the treatment of OA
including etodolac and meloxicam which are relatively COX-2
selective, and rofecoxib, celecoxib, valdecoxib, etoricoxib, and
lumiracoxib which are highly COX-2 selective. 
A review of the efficacy and safety of the COX-2 inhibitors is
beyond the scope of this article. Therefore, only the major issues
(i.e. their GI effects and potential CV risk) currently surrounding
the COX-2 inhibitors will be summarized. 
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GI effects
There is conflicting data regarding the GI benefit of COX-2
inhibitors compared with the nonselective NSAIDs. Large-scale
GI safety studies with rofecoxib [Vioxx Gastrointestinal
Outcomes Research (VIGOR) trial] and celecoxib [Celecoxib
Long-term Arthritis Safety Study (CLASS)] have demonstrated
that these COX-2 inhibitors reduce the incidence of GI adverse
events compared with nonselective NSAIDs (Bombardier et al.
2000; Silverstein et al. 2000). However, unpublished data from
the CLASS trial have shown that the GI advantage seen with
celecoxib at 6 months was not evident after 13 months (FDA
2001). In addition, a review of data from an observational study
of 367 general practices in the UK suggested that rofecoxib did
not offer a GI benefit over the nonselective NSAIDs (Hippisley-
Cox et al. 2005).
CV profile
COX-2 inhibitors appear to suppress the production of
prostacyclin, a vasodilator that inhibits platelet aggregation 
and thereby reduces blood clotting. It has been hypothesized 
that selective inhibition of COX-2 may alter the balance between 
the antithrombotic prostacyclin and prothrombotic TXA2,
selectively inhibiting the production of prostacyclin and allowing
the effects of thromboxane to predominate, thereby promoting a
prothrombotic state (Jones 2005). 
Emerging data have raised concerns over an increased risk of CV
events with COX-2 inhibitors. Data from the cancer prevention
trial Adenomatous Polyp Prevention on Vioxx (APPROVe)
suggested that patients receiving rofecoxib had a statistically
significant increase in heart attacks and other adverse CV events
such as strokes (Bresalier et al. 2005). It is not evident whether
the increased risk of CV events seen with rofecoxib is a class
effect. However, the Adenoma Prevention with Celecoxib (APC)
trial also demonstrated 2.5 times the rate of a major CV event
among patients taking celecoxib compared with placebo
(Solomon et al. 2005), and there is some evidence for increased
CV risk with another COX-2 inhibitor, ertoricoxib (Aldington et al.
2005). A systematic review of the clinical literature (from 1996 to
March 2005) attempted to determine the relative
thromboembolic risks of COX-2 inhibitors and concluded that
each COX-2 inhibitor has a unique CV risk profile (Jones 2005).
The author noted that the risk of a CV event may depend upon
the agent chosen and its COX-2-specific isoform-binding affinity,
the CV risk profile of the patient, and the dose and duration of the
drug use. 
Renal function
In addition to the role of COX-1, COX-2 is also involved in the
synthesis of prostaglandins which play a role in modulating renal
function. Consequently COX-2 inhibitors have been associated
with similar renal adverse effects to those seen with nonselective
NSAIDs. Therefore, the COX-2 inhibitors may not offer a clinical
advantage over nonselective NSAIDs with regards to avoiding or
exacerbating edema, hypertension, and congestive heart failure. 
The COX-2 inhibitors rofecoxib and celecoxib have been
associated with slightly higher BP compared with nonselective
NSAIDs (Whelton et al. 2001; Whelton et al. 2002; Aw et al. 2005).
A retrospective cohort study demonstrated that more elderly
patients with a previous episode of congestive heart failure
prescribed celecoxib survived or remained free of recurrent
congestive heart failure than those prescribed either rofecoxib or
nonselective NSAIDs. These data suggest that differences may
exist between the classes of nonselective NSAIDs and COX-2
inhibitors, and between COX-2 inhibitors (Hudson et al. 2005). 
Current treatment guidelines
It is recommended that all pharmacologic agents should be
considered in addition to nonpharmacologic measures for the
treatment of OA. The first drug of choice for the treatment of
inflammation and pain in patients with OA is acetaminophen,
which when using the appropriate dosage may be taken safely
over the long term, and is inexpensive compared with prescription
NSAIDs (ACR 2000; Pendleton et al. 2000; NICE 2001).
Alternatively, US guidelines for the medical management of OA of
the hip and knee suggest that NSAIDs or joint aspiration in
combination with intraarticular injection of glucocorticoids may 
be considered as first-line pharmacologic therapy in patients with
moderate to severe pain, and with signs of joint inflammation (ACR
2000). In patients with risk factors for serious upper 
GI events and renal toxicity, US guidelines recommend the use of
COX-2 selective inhibitors, or nonselective NSAIDs in combination
with a gastroprotective agent (misoprostol or a PPI) (ACR 2000).
European (EULAR) evidence-based guidelines for the management
of knee OA state that there is good evidence [from at least one
randomized, controlled trial (RCT)] to suggest that NSAIDs are more
efficacious in providing pain relief than acetaminophen (Pendleton
et al. 2000). In patients who fail to achieve adequate symptomatic
relief with acetaminophen, European guidelines recommend the
use of oral or topical NSAIDs (Pendleton et al. 2000). 
Current NICE guidelines on the use of COX-2 inhibitors (celecoxib,
rofecoxib, meloxicam, and etodolac) do not recommend the
routine use of COX-2 selective inhibitors in patients with OA (NICE
2001). These guidelines state that they should only be used
instead of nonselective NSAIDs in patients at high-risk of
developing serious GI adverse effects (patients aged ≥65 years,
using concomitant medication that increases the likelihood of
upper GI adverse events, serious comorbidity present, or requiring
prolonged use of maximum recommended doses of NSAIDs). 
It is assumed that these recommendations are based upon the
improved cost effectiveness reported with COX-2 inhibitors in this
high-risk population, compared with nonselective NSAIDs.
Since the publication of these guidelines, rofecoxib and valdecoxib
have been withdrawn from all markets (Table 2). A joint meeting of
the Arthritis Advisory Committee and the Drug Safety and Risk
Management Advisory Committee reviewed the safety of all COX-2
inhibitors (FDA 2005a). They concluded that the risk versus benefit
of COX-2 inhibitors favored their continued use in the US and that
although all NSAIDs impose similar CV risks, some agents
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(e.g. rofecoxib, valdecoxib, diclofenac, and ibuprofen). They also
concluded that the CV risks of COX-2 inhibitors may be greater with
higher doses, longer durations of therapy, and when used in 
high-risk individuals. Therefore, they suggested that the use of 
COX-2 inhibitors and other NSAIDs thought to increase CV risk
should be avoided in high-risk individuals. As a result of this
meeting, the Food and Drug Administration (FDA) has issued a
Public Health Advisory on CV risks from all nonaspirin NSAIDs and
recommended the addition of “black box” label warnings for CV risks
and GI bleeding for all prescription nonaspirin NSAIDs (FDA 2005b).
Similar contraindications and precautions have been recommended
by the European Medicines Agency (EMEA 2005a) (Table 2).
Unmet needs
The pain and joint stiffness associated with OA has debilitating
effects on patients, seriously affecting their quality of life.
Therefore, patients require a drug which effectively reduces pain
and stiffness, and is safe and well tolerated in the long term.
Current treatment options for OA are limited. Nonselective
NSAIDs can cause GI adverse events, and are often used in
combination with gastroprotective agents. This increases the
medication burden, and may lead to cost issues. A large
proportion of patients with OA are ≥65 years of age, and are likely
to be receiving multiple medications for concomitant conditions.
Therefore, this medication burden may also lead to 
compliance issues. 
The COX-2 inhibitors provided an alternative treatment to
nonselective NSAIDs, particularly for patients at high risk of GI
events. However, the withdrawal of rofecoxib and valdecoxib,
because of concerns over CV safety and the potential for a rare but
serious skin reaction with valdecoxib, has limited the treatment
options available for patients with OA as indicated in Table 2.
Celecoxib is the only COX-2 inhibitor available in the US, and the
potential risk of CV events has restricted its use in patients with
CV disease. 
Many patients with OA are elderly with comorbidities such as CV
disease. Therefore, there is a need for an agent which is as
effective as an NSAID, has a low incidence of GI events, is more
cost effective than nonselective NSAIDs in combination with
gastroprotective agents, and has a good safety profile. 
Clinical evidence with lumiracoxib in OA
Lumiracoxib is a selective COX-2 inhibitor and, unlike the other
COX-2 inhibitors (sulfonamides or sulfone derivatives), it is an
arylacetic acid derivative (Rordorf et al. 2005). Therefore, it is
unlikely to cause an allergic reaction in patients with a
hypersensitivity to sulfonamides. 
Most data in the form of patient-oriented evidence have been
gained from large, randomized, controlled clinical studies with
lumiracoxib in patients with OA. Improved quality of life, provided
by pain relief and improvements in joint stiffness, is an important
outcome in patients with OA. The physical functioning of patients
with lumiracoxib has been measured in the majority of studies by
the Western Ontario and McMaster Universities OA Index
(WOMAC) questionnaire for patients with OA of the knee or hip
and by the Australian/Canadian OA Hand Index (AUSCAN) for
patients with OA of the hand. Two studies have also utilized the
Short Form (SF) 36 Health Survey to assess health-related quality
of life, and one pooled analysis employs a scale called the Patient
Acceptable Symptom State (PASS).
Pain intensity 
Strong level 1 evidence from a systematic review of nine RCTs
(Berenbaum et al. 2005), level 2 evidence from three RCTs
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Design Treatment 
(no. patients)
PID (100 mm VAS); baseline to mean
of 3- and 5-hour pain assessments
after dosing on day 0
1-wk, parallel-
group RCT
400 mg LX od (144)
200 mg CX bid (145)
PL (75)
19.8
16.8
13.4
1-wk, parallel-
group RCTa
200 mg LX od (105)
400 mg LX od (99)
200 mg CX bid (101)
PL (103)
19.6 
17.8 
17.8 
15.4
aAlso published in abstract form (Wittenberg et al. 2003).
bid, twice daily; CX, celecoxib; LX, lumiracoxib; OA, osteoarthritis; od, once daily; PID,
pain intensity difference; PL, placebo; RCT, randomized controlled trial; VAS, visual 
analog scale; wk, week.
Table 3 | Level 1 evidence (taken from a systematic review of
nine efficacy studies) of the effect of lumiracoxib on
pain intensity in patients with OA of the knee
(Berenbaum et al. 2005)
Drug Current satus
Lumiracoxib
(Prexige, Novartis)
Approved in EU, Argentina, Brazil, Mexico,
South Africa; withdrawn in Australia, Canada
Celecoxib
(Celebrex, Pfizer)
Only marketed COX-2 inhibitor in the US
Restricted use in EUa
Etoricoxib
(Arcoxia, Merck)
Not available in US
Valdecoxib
(Bextra, Pfizer)
Withdrawn from US (April 2005), suspended 
in EU
Rofecoxib
(Vioxx, Merck)
Withdrawn from all markets following results
from the APPROVe trial (September 2004)
aThe use of COX-2 inhibitors has been restricted in the EU with several contraindications
and precautions (EMEA 2005a), as follows: COX-2 inhibitors must not be used in patients
with established ischemic heart disease and/or cerebrovascular disease (stroke) and in
patients with peripheral arterial disease. Healthcare professionals (HCPs) to exercise
caution in prescribing COX-2 inhibitors to patients with risk factors for heart disease, such
as hypertension, hyperlipidemia, diabetes, and smoking. Advised to use lowest effective
dose for shortest possible duration of treatment. Warnings to HCPs and patients that
hypersensitivity reactions and rare, but serious and sometimes fatal, skin reactions can
occur with all COX-2 inhibitors. In the majority of cases these occur in the first month of
treatment and patients with a history of drug allergies may be at greater risk. 
APPROVe, Adenomatous Polyp Prevention on Vioxx; COX-2, cyclooxygenase-2.
Table 2 | Current status (October 2007) of COX-2 inhibitors 
for the treatment of OA 137
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Table 4 | Effect of lumiracoxib on pain intensity and patient’s/physician’s global assessment of disease activity in patients with OA of 
the knee, hip or hand (all published level 2 evidence is cited as original source; level 2 evidence only published within the
systematic review of Berenbaum et al. 2005 is cited as such)
Reference Design and 
population
Treatment 
(no. patients)
Outcome [mean change from baseline to end of study (100 mm VAS)]
Pain intensity in 
target knee (mm)
Patient’s global
assessment of 
disease activity (mm)
Physician’s global
assessment of 
disease activity (mm)
4-week studies
Berenbaum et al. 2005a Hip or knee OA 
db, RCT
100 mg LX od (122)
PL (122)
–24.6 
–16.8
LX–PL difference in LSM
–8.8; P=0.001
NR
Schnitzer et al. 2004a Hip or knee OA 
Phase II dose-
finding study
db, RCT
50 mg LX bid (98)
100 mg LX bid (96)
200 mg LX bid (99)
400 mg LX od (99)
75 mg diclofenac bid (94)
PL (97)
Mean overall scores at
baseline of 64.7–67.0 
were reduced to 33.7–
38.4 mm with all doses
of LX and diclofenac,
and from 67.9 to 50.2
with placebo
–24.3
–24.2
–26.5
–28.1
–27.8
–12.5
–21.8
–23.2
–27.0
–26.5
–23.8
–13.1
Grifka et al. 2004 Hand OA 
db, mc, RCT
200 mg LX od (205)
400 mg LX od (193)
PL (196)
–28.0
–30.0
–19.3
–16.3
–20.9
–9.4
–17.8
–18.7
–12.5
13-week studies
Lehmann et al. 2005 Knee OA 
db, dd, mc, RCT
100 mg LX od (420)
100 mg LX od + 200 mg loading
dose LX od for first 2 wk (420)
200 mg CX od (420)
PL (424)
–26.8
–26.2
–26.6
–21.4
–25.1
–21.9
–22.9
–18.9
–26.3
–25.0
–25.4
–20.4
Sheldon et al. 2005 Knee OA 
db, dd, mc, RCT
100 mg LX od (391)
100 mg LX od + 200 mg loading
dose LX od for first 2 wk (385)
200 mg CX od (393)
PL (382)
–25.1
–25.9
–24.1
–18.1
–23.2
–24.6
–19.5
–13.4
–25.5
–26.9
–22.2
–15.7
Tannenbaum et al. 2004 Knee OA 
db, dd, mc, RCT
200 mg LX od (487)
400 mg LX od (491)
200 mg CX od (481)
PL (243)
–26.0
–27.4
–25.2
–19.8
–23.2
–24.1
–22.4
–15.7
–23.0
–23.6
–22.4
–18.0
Fleischmann et al. 2005 Knee OA 
db, dd, mc, RCT
200 mg LX od (462)
400 mg LX od (463)
200 mg CX od (444)
PL (231)
–28.7
–29.7
–27.4
–21.3
–25.3
–25.8
–24.5
–16.1
–27.2
–26.7
–24.5
–18.3
Berenbaum et al. 2005 Hip OA 
RCT
400 mg LX od (205)
25 mg RX od (102)
PL (204)
–21.8
–25.0
–15.1
–18.3
–21.8
–11.6
NR
NR
NR
52-week studies
Berenbaum et al. 2005b Knee OA 
39-wk extension
of Tannenbaum
et al. 2004
200 mg LX od (352)
400 mg LX od (358)
200 mg CX od (348)
200 mg LX od (56)c
400 mg LX od (59)c
200 mg CX od (56)c
–28.1
–28.7
–28.3
–3.3
–5.6
–4.3
–25.2
–24.6
–26.1
–5.2
–5.8
–9.2
NR
NR
NR
NR
NR
NR
Pavelka et al. 2005
(abstract)
Knee OA 
39-wk extension
of Lehmann et al.
2005
100 mg LX od (659)
200 mg CX od (327)
100 mg LX od (176)d
200 mg CX od (130)d
LSM for LX and CX
were similar at study
end: 33.2 mm and 
31.0 mm, respectively
LSM for LX and CX were
similar at study end: 
36.6 mm and 34.2 mm,
respectively
NR
Schnitzer et al. 2004b,
Grifka et al. 2005
(abstract)
Hip, knee, or
hand OA
400 mg LX od (9117)
500 mg naproxen bid (4730)
800 mg ibuprofen tid (4397)
Reduction in pain
intensity with LX was
similar to that of
NSAIDs [62.7% vs
61.9% (NSAID
combined data);
P=0.107], regardless of
the joint affectede
Proportion of patients
with improvement in the
patient’s global
assessment of disease
activity: 60.3% LX vs
59.1% (ibuprofen and
naproxen; P=0.015)e
Proportion of patients
with improvement in the
physician’s global
assessment of disease
activity: 59.2% LX vs
58.3% (ibuprofen and
naproxen; P=0.023)
aAlso published in abstract form (Benevolenskaya et al. 2003); bAlso published in abstract form (Schell et al. 2003); c171 patients receiving placebo during the core 13-week study were re-randomized to active
treatment during extension period; d306 patients receiving placebo during the core 13-week study were re-randomized to active treatment during extension period; eAll data scored using the 5-point Likert scale.
bid, twice daily; CX, celecoxib; db, double-blind; dd, double-dummy; LSM, least squares mean; LX, lumiracoxib; mc, multicenter; NSAID, nonsteroidal antiinflammatory drug; NR, not reported; OA, osteoarthritis;
od, once daily;PL, placebo; RCT, randomized controlled trial; RX, rofecoxib; tid, three times daily; VAS, visual analog scale; wk, week.Lumiracoxib | clinical impact review
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Reference Design and 
population
Treatment 
(no. patients)
Outcome (mean change from baseline to end of study)
WOMAC scores (AUSCAN for OA of hand)
Total score Pain subscale DPDA subscale Stiffness subscale
4-week studies
Berenbaum et al. 2005a Hip or knee OA 
db, RCT
100 mg LX od (122)
PL (122)
LX–PL difference in LSM 
–4.5; P=0.021
NR NR NR
Schnitzer et al. 2004a Hip or knee OA 
Phase II dose-
finding study
db, RCT
50 mg LX bid (98)
100 mg LX bid (96)
200 mg LX bid (99)
400 mg LX od (99)
75 mg diclofenac bid (94)
PL (97)
NR
NR
NR
NR
NR
NR
–3.4
–2.8
–3.2
–3.8
–3.3
–1.5
–10.3
–7.9
–10.7
–13.0
–11.1
–5.4
–1.7
–1.3
–1.5
–1.6
–1.3
–0.7
Grifka et al. 2004 Hand OA 
db, mc, RCT 
200 mg LX od (205)
400 mg LX od (193)
PL (196)
–7.7
–10.5
–5.6
–3.0
–3.9
–2.1
–4.3
–6.0
–3.1
–0.6
–0.7
–0.4
13-week studies
Lehmann et al. 2005 Knee OA 
db, dd, mc,
RCT
100 mg LX od (420)
100 mg LX od + 200 mg loading
dose LX od for first 2 wk (420)
200 mg CX od (420)
PL (424)
–15.2
–14.8
–14.7
–11.3
–3.4
–3.2
–3.4
–2.5
–10.5
–10.4
–10.3
–8.0
–1.3
–1.1
–1.1
–0.9
Sheldon et al. 2005 Knee OA 
db, dd, mc,
RCT
100 mg LX od (391)
100 mg LX od + 200 mg loading
dose LX od for first 2 wk (385)
200 mg CX od (393)
PL (382)
–16.9
–17.2
–15.6
–9.5
–3.6
–3.7
–3.4
–2.3
–11.9
–12.0
–10.8
–6.3
–1.5
–1.5
–1.4
–0.9
Tannenbaum et al. 2004 Knee OA 
db, dd, mc,
RCT
200 mg LX od (487)
400 mg LX od (491)
200 mg CX od (481)
PL (243)
–14.1
–14.1
–13.4
–9.4
–3.2
–3.2
–3.1
–2.4
–9.8
–9.7
–9.2
–6.2
–1.2
–1.2
–1.2
–0.9
Fleischmann et al. 2005 Knee OA 
db, dd, mc,
RCT
200 mg LX od (462)
400 mg LX od (463)
200 mg CX od (444)
PL (231)
–17.8
–16.9
–16.0
–9.3
–3.7
–3.7
–3.5
–2.3
–12.5
–11.7
–11.0
–6.1
–1.6
–1.4
–1.4
–0.9
Berenbaum et al. 2005 Hip OA 
RCT
400 mg LX od (205)
25 mg RX od (102)
PL (204)
–11.4
–14.6
–8.6
–2.7
–3.1
–2.1
NR
NR
NR
NR
NR
NR
52-week studies
Berenbaum et al. 2005b Knee OA 
39-wk extension
of Tannenbaum
et al. 2004
200 mg LX od (352)
400 mg LX od (358)
200 mg CX od (348)
200 mg LX od (56)c
400 mg LX od (59)c
200 mg CX od (56)c
–16.1
–16.4
–15.5
–3.5
–2.1
–5.9
–3.6
–3.7
–3.4
–0.4
–0.5
–1.5
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
Pavelka et al. 2005
(abstract)
Knee OA 
39-wk extension
of Lehmann 
et al. 2005
100 mg LX od (659)
200 mg CX od (327)
100 mg LX od (176)d
200 mg CX od (130)d
LSM for LX and CX were
similar at study end:
33.0 mm and 30.7 mm,
respectively
NR NR NR
aAlso published in abstract form (Benevolenskaya et al. 2003).
bAlso published in abstract form (Schell et al. 2003).
c171 patients receiving placebo during the core 13-week study were re-randomized to active treatment during the extension period.
d306 patients receiving placebo during the core 13-week study were re-randomized to active treatment during the extension period.
AUSCAN, Australian/Canadian OA Hand Index; bid, twice daily; CX, celecoxib; db, double-blind; dd, double-dummy; DPDA, difficulty in performing daily activities; LSM, 
least squares mean; LX, lumiracoxib; mc, multicenter; NR, not reported; OA, osteoarthritis; od, once daily; PL, placebo; RCT, randomized controlled trial; RX, rofecoxib; wk, week; 
WOMAC, Western Ontario and McMaster Universities OA Index.
Table 5 | Effect of lumiracoxib on WOMAC/AUSCAN scores in patients with OA of the knee, hip, or hand (all published level 2
evidence is cited as original source; level 2 evidence only published within the systematic review of Berenbaum et al. 2005
is cited as such)published in full, including the Therapeutic Arthritis Research and
Gastrointestinal Event Trial (TARGET) (Schnitzer et al. 2004b;
Lehmann et al. 2005; Sheldon et al. 2005), one RCT published in
abstract form (Pavelka et al. 2005), and an additional analysis
from TARGET published in abstract form (Grifka et al. 2005), has
shown that the pain relief [as assessed by pain intensity on a
visual analog scale (VAS)] with lumiracoxib is superior to that
gained with placebo and similar to that with celecoxib, rofecoxib,
ibuprofen, naproxen, and diclofenac in patients with OA of the
hand, hip, or knee (Tables 3 and 4). The efficacy of lumiracoxib
does not appear to be dose dependent, with the 100 mg dose
providing similar efficacy to the 400 mg dose. 
Level 1 and level 2 evidence from these studies also shows that
lumiracoxib improves patients’ and physicians’ assessment 
of disease activity, as determined by a questionnaire (Table 4). 
The reduction in scores with lumiracoxib were superior to placebo
and comparable with celecoxib, rofecoxib, ibuprofen, naproxen,
and diclofenac. These findings suggest that lumiracoxib is
effective in managing pain relief in patients with OA, and has
comparable efficacy to other available NSAIDs.
Pain intensity was reduced by lumiracoxib 400 mg/day (four times
greater than the recommended dosage for OA) to a significantly
greater extent than placebo and to a comparable degree as
celecoxib 200 mg/day (twice the recommended OA dosage) 3 and
5 hours postdose in patients with knee OA (Wittenberg et al. 2006).
Joint stiffness and function 
Level 1 (Berenbaum et al. 2005) and level 2 evidence (Lehmann et
al. 2005; Sheldon et al. 2005) demonstrated that lumiracoxib
improves joint stiffness and overall function [assessed using the
difficulty in performing daily activities (DPDA) and stiffness
subscales of the WOMAC questionnaire or the AUSCAN]
compared with placebo (Table 5). These improvements were similar
to that achieved with diclofenac and celecoxib, and are expected
to have a positive impact on the quality of life of the patient.
SF-36 Health Survey
The SF-36 Health Survey is a validated questionnaire which
provides a measure of generic health by eight health profiles
including physical functioning and mental health (Ware 1993). 
SF-36 was used in two RCTs to determine health-related quality of
life in patients with OA receiving lumiracoxib (Fleischmann et al.
2005; Sheldon et al. 2005). The results showed that lumiracoxib and
celecoxib were statistically superior to placebo in the SF-36 physical
component (data not reported; defined as limitations in physical
activity because of health problems) (Fleischmann et al. 2005;
Sheldon et al. 2005) and mental health component (defined as
psychologic distress and wellbeing) (Sheldon et al. 2005) 
at week 13. 
Responders
Analyses of response to lumiracoxib treatment were also performed
using the Outcome Measures in Clinical Trials-Osteoarthritis
Research Society International (OMERACT-OARSI) criteria
(Dougados et al. 2000; Pham et al. 2003). Responders 
to treatment were defined as patients who either had: 
a) reduction of ≥50% from baseline and an absolute reduction of ≥20
either in OA pain intensity (100 mm VAS) or WOMAC DPDA
subscale score (rescaled to 0–100); or b) reduction of ≥20% and an
absolute reduction of ≥10 in at least two of the following variables:
OA pain intensity (100 mm VAS), WOMAC DPDA subscale score
(rescaled to 0–100) or patient’s global assessment of disease activity
(100 mm VAS). These criteria demonstrated that a significantly
greater proportion of patients receiving active treatment were
considered responders compared with placebo (data not stated,
reported graphically; all P<0.05 vs placebo) (Berenbaum et al. 2005;
Fleischmann et al. 2005; Lehmann et al. 2005; Sheldon et al. 2005).
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Lumiracoxib 100 mg/day
(n=811)
Lumiracoxib 100 mg/day with
initial dose of 200 mg/day 
(n=805)
Celecoxib 200 mg/day
(n=813)
Placebo
(n=806)
Pain intensity
Week 2 30.9a 33.5a 29.8a 17
Week 13 43.3a 45.3a 42.2b 35.5
Disease activity
Week 2 29.6a 31.7a 28.8a 17.4
Week 13 42.8a 43.9a 39.5a 31.6
WOMAC function score
Week 2 32.3a 33.7a 31.9a 19.1
Week 13 41.6a 41.4a 38.7a 29.5
aP<0.001 vs placebo.
bP<0.01 vs placebo.
WOMAC, Western Ontario and McMuster Universities OA Index.
Table 6 | Patient satisfaction (%) with lumiracoxib 100 mg/day versus celecoxib 200 mg/day according to Patient Acceptable
Symptom State (PASS). Pooled analysis of Lehmann et al. (2005) and Sheldon et al. (2005) (from Dougados et al. 2007)A pooled analysis of the trials by Lehmann et al. (2005) and
Sheldon et al. (2005) investigated the response to treatment using
PASS (Dougados et al. 2007). PASS defines the symptom score
beyond which patients consider themselves to be well (0–100 mm
VAS): ≤32.3 mm for pain intensity, ≤32 mm for disease activity,
and ≤21.08  for WOMAC function score. A significantly greater
proportion of patients receiving lumiracoxib 100 mg/day, with and
without an initial dose of 200 mg/day, were satisfied after 
2 and 13 weeks compared with placebo; there was no significant
difference between lumiracoxib and celecoxib 200 mg/day 
(Table 6). The response rate, measured by Minimally Clinical
Important Improvement (MCII) in a patient’s symptom score, was
similar for lumiracoxib and celecoxib, and significantly greater
than with placebo (Dougados et al. 2007). 
General tolerability
The most common adverse events with lumiracoxib in clinical
trials typically included headache and nasopharyngitis. As
expected, GI effects were also present, with nausea, diarrhea,
dyspepsia, and upper abdominal pain being the most frequent
minor GI-related adverse events. The incidence of these adverse
events was similar to that with celecoxib, diclofenac, ibuprofen,
and naproxen. TARGET is the only long-term study assessing the
safety of lumiracoxib over 52 weeks in a large population of
patients (9117 receiving lumiracoxib treatment). Table 7 provides
details of the adverse events experienced with lumiracoxib in this
study. Discontinuation due to adverse events was similar between
active treatment groups and placebo, although there were a
greater number of discontinuations with diclofenac than
lumiracoxib (14% vs 3–5%) in one RCT (Schnitzer et al. 2004a). In
addition, Schnitzer et al. (2004a) reported that there was no
dosage-related trend with lumiracoxib in the incidence of these
adverse events.  
GI safety 
Evidence suggests that lumiracoxib is associated with a
comparable incidence of GI complications to other COX-2
inhibitors, and a lower risk of upper GI ulcer complications
compared with ibuprofen or naproxen in patients not taking
aspirin. 
Level 1 evidence from a pooled analysis of 15 phase II and phase
III RCTs in patients with OA or RA, demonstrated that treatment
with lumiracoxib (100–1200 mg; 5439 patients) was associated
with a significantly lower rate of perforations, obstructions,
symptomatic ulcers, and bleedings than the nonselective NSAIDs
(1.7 versus 13.7 events per 100 patient-years for lumiracoxib
200–400 mg) (Hawkey et al. 2006) (Table 8). The incidence was
similar to that for celecoxib and rofecoxib (1.4 events per 100
patient-years). 
Level 2 evidence from two RCTs of short duration (8 days) in
healthy volunteers showed that lumiracoxib (200 or 800 mg) is
associated with a lower incidence of gastric and duodenal
erosion, compared with the nonselective NSAID naproxen
(Rordorf et al. 2003; Atherton et al. 2004; Table 8). In addition,
results from a study of 13 weeks’ duration in patients with OA
demonstrated that lumiracoxib 200 or 400 mg was associated
with a significant lower incidence of gastroduodenal ulcers 
(≥3 mm and ≥5 mm) compared with the nonselective NSAID
ibuprofen (P<0.001 and P<0.005, respectively), a similar
incidence to that achieved with celecoxib (Hawkey et al. 2004a). 
Gastric erosion is a surrogate marker for the development of
peptic ulceration or other major GI adverse effects. Therefore,
the TARGET outcomes study in 18 325 patients with OA was
conducted to determine the clinical relevance of these
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Outcome Lumiracoxib vs ibuprofen substudy Lumiracoxib vs naproxen substudy
Lumiracoxib 
(n=4376)
Ibuprofen 
(n=4397)
Lumiracoxib 
(n=4741)
Naproxen 
(n=4730)
Total number of patients with AEs 3586 (82%) 3559 (81%) 3647 (77%) 3717 (79%)
Total number of patients with SAEs 297 (7%) 272 (6%) 291 (6%) 294 (6%)
Prespecified GI events 1855 (42%) 1851 (42%) 1785 (38%) 1988 (42%)
dyspepsia 1230 (28%) 1205 (27%) 1037 (22%) 1119 (24%)
abdominal pain upper 380 (9%) 452 (10%) 535 (11%) 695 (15%)
diarrhea 285 (7%) 247 (6%) 273 (6%) 195 (4%)
nausea 244 (6%) 261 (6%) 221 (5%) 264 (6%)
abdominal pain 147 (3%) 153 (4%) 181 (4%) 187 (4%)
Discontinuations due to AEs (including SAEs) 718 (16%) 802 (18%) 723 (15%) 855 (18%)
AE, adverse event; GI, gastrointestinal; OA, osteoarthritis; SAE, serious adverse event.
Table 7 | Level 2 evidence for the most common adverse events and discontinuations due to adverse events with lumiracoxib in
patients with hip, knee or, hand OA (Schnitzer et al. 2004b)141
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Table 8 | Evidence for the incidence of GI erosions and ulcers with lumiracoxib
Reference Design and population Treatment (no.) Incidence of GI erosions and ulcers
Level 1 evidence 
Hawkey et al. 2006 Pooled analysis (15 phase II and 
III RCTs)
Pts with hip, knee, hand, or spine 
OA, or symptomatic RA pts
1–52 wk, db, RCT
100–1200 mg LX od
200/400 mg CX od
25 mg RX od
75 mg diclofenac bid
800 mg ibuprofen tid
500 mg naproxen bid
PL
Incidence of PUBs: 1.7 events per 100 patient-years, LX 200/400 mg; 
1.4 events per 100 patient-years, celecoxib and rofecoxib; 13.7 events 
per 100 patient-years, nonselective NSAIDs
Frequency of symptomatic ulcers: 0.4% LX 200/400 mg, 0.4% CX and
RX, 2.5% nonselective NSAIDs
Endoscopic studies: level 2 evidence
Atherton et al. 2004 Healthy volunteers
8 d, db, dd, RCT (3-way
crossover; 18-d washout period)
800 mg LX od (24)
PL (24)
500 mg naproxen bid (24)
No subjects receiving LX developed gastroduodenal erosions
3 subjects (12.5%) on PL developed gastroduodenal erosions 
(1–6 erosions per individual)
18 subjects (75%) on naproxen had a total of 255 gastroduodenal
erosions (1–32 erosions per individual). Erosions were predominantly 
in the gastric antrum
Rordorf et al. 2003 Healthy male volunteers
8 d, db, dd, RCT
200 mg LX bid (20)
PL (20)
500 mg naproxen bid (20)
No duodenal erosions (endoscopy grade 3 or above) with LX or PL
13/20 (65%) pts had duodenal erosions with naproxen
No gastric erosions with LX
One subject in naproxen group developed an asymptomatic gastric ulcer
One subject in PL group developed a grade 4 gastric erosion (6–10 erosions)
Hawkey et al. 2004a Pts with hip, knee, or hand OA
13 wk, db, dd, mc, RCT
200 mg LX od (257)a
400 mg LX od (253)a
800 mg ibuprofen tid
(248)a
200 mg CX od (253)a
The cumulative incidence of gastroduodenal ulcers (≥3 mm diameter) 
was 4.3% and 4.0% for 200 mg LX and 400 mg LX, respectively 
(both P<0.001 vs ibuprofen), 15.7% for ibuprofen and 3.2% for CX
The cumulative incidence of gastroduodenal ulcers (≥5 mm diameter) 
was 3.9% and 3.6% for 200 mg LX and 400 mg LX, respectively 
(both P<0.005 vs ibuprofen), 12.5% for ibuprofen and 2.8% for CX
The number of pts with >10 gastroduodenal erosions was significantly
greater with ibuprofen (6%) compared with 200 mg LX (1.2%; P<0.01), 
400 mg LX (1.6%, P<0.05), and CX (2.4%, P<0.05)
72.4% and 76.7% of pts receiving 200 mg LX and 400 mg LX, respectively
had no visible injury of gastric mucosa compared with 55.2% of pts receiving
ibuprofen (both P<0.001 vs ibuprofen) and 75.5% of pts receiving CX
83.7% and 87.4% of pts receiving 200 mg LX and 400 mg LX,
respectively, had no visible injury of gastric mucosa compared with 
74.2% of pts receiving ibuprofen (P<0.05 LX 200 mg, P<0.001 LX 400 mg
vs ibuprofen) and 87.7% of pts receiving CX
Lower level mucosal injury: only one pt developed an esophageal ulcer 
(LX 400 mg)
Outcome study: level 2 evidence
Schnitzer et al.
2004b
Pts with hip, knee, hand, or spine
OA
52 wk, db, dd, mc, RCT
400 mg LX od (4376)
800 mg ibuprofen 
tid (4397)
400 mg LX od (4741)
500 mg naproxen 
bid (4730)
Number (incidence) of upper GI ulcer complicationsb: 10 (0.23%) LX vs 
33 (0.75%) ibuprofen (HR 0.29; P=0.0006); 19 (0.40%) LX vs 50 (1.06%)
naproxen (HR 0.37; P=0.0002). The majority of these GI complications
were presented as melena or hematochezia
Number (incidence) of upper GI ulcer complications in nonaspirin populationb:
5/3401 (0.15%) LX vs 28/3431 (0.82%) ibuprofen (HR 0.17; P=0.0003); 9/3549
(0.25%) LX vs 36/3537 (1.02%) naproxen (HR 0.24; P=0.0001)
Number (incidence) of upper GI ulcer complications in aspirin populationb:
5/975 (0.51%) LX vs 5/966 (0.52%) ibuprofen (HR 0.92; P=0.9008);
10/1192 (0.84%) LX vs 14/1193 (1.17%) naproxen (HR 0.73; P=0.4502)
Number (incidence) of symptomatic uncomplicated ulcersc: 58/9117
(0.64%) LX vs 103/9127 (1.13%) nonselective NSAIDs (HR 0.55; P=0.0003)
aModified safety population (defined as all patients who underwent at least one postbaseline endoscopy). 
bDefinite or probable upper GI ulcer complications (clinically significant bleeding, perforation, or obstruction from erosive or ulcer disease).
cUlcers discovered when endoscopy was done for dyspepsia.
bid, twice daily; CX, celecoxib; d, day; db, double-blind; dd, double-dummy; GI, gastrointestinal; HR, hazard ratio; LX, lumiraoxib; mc, multicenter; NSAIDs, nonsteroidal antiinflammatory
drugs; OA, osteoarthritis; od, once daily; PL, placebo; pts, patients; PUBs, perforations, obstructions, symptomatic ulcers, and bleedings; RA, rheumatoid arthritis; RCT, randomized controlled
trial; RX, rofecoxib, RCT;  tid, three times daily; wk, week.endoscopic findings (Schnitzer et al. 2004b; Hawkey et al.
2004b; Table 8). This study showed that patients receiving
lumiracoxib at a dose of 400 mg, which is four-fold greater than
the currently indicated dosage of 100 mg for OA, had a
significantly lower risk of upper GI ulcer complications than
patients receiving ibuprofen or naproxen. In contrast, in patients
receiving low-dose aspirin (75–100 mg/day), the incidence of
ulcer complications with lumiracoxib was similar to that with
ibuprofen and naproxen, and provided no additional GI benefit. 
It has been determined that using lumiracoxib rather 
than ibuprofen or naproxen for 1 year would prevent one 
severe upper GI event for every 170 patients treated 
(nonaspirin and aspirin populations combined) (Bannwarth &
Berenbaum 2005). In comparison, in the nonaspirin population
lumiracoxib would prevent one severe upper GI event for every 
139 patients treated.
Cardiovascular safety
Weak level 1 evidence from a meta analysis of 22 RCTs ranging
from ≥1 week and up to 1 year in duration in patients with either
OA or RA found no evidence that lumiracoxib was associated 
with a significant increase in risk for a CV event compared with
naproxen, other NSAIDs (diclofenac, ibuprofen, celecoxib,
rofecoxib) or placebo (Matchaba et al. 2005; Table 9). A total of 
15 studies were in patients with OA. The incidence of CV events
in patients with OA is provided in Table 10. 
The evidence from this meta analysis is weak because the
majority of the studies reported were of 4 or 13 weeks’
duration. Few CV events were reported with lumiracoxib during
this period (Table 10), and it is unlikely that evidence of CV
events would be demonstrated after such a short period of
drug exposure. Only TARGET was of adequate duration (1 year)
to provide meaningful level 2 evidence for the incidence of 
CV events with lumiracoxib. However, 1 year may be not
sufficient to determine long-term CV risk, and studies of longer
duration may be required. Furthermore, a major shortcoming of
TARGET was the exclusion of patients with a history of CV
disease. Only patients at increased risk of coronary heart
disease were eligible provided that they had received low-
dose aspirin (75–100 mg daily) for a minimum of 3 months prior 
to randomization. 
Of the 34 668 patients included in this meta analysis, 18 325 were
from TARGET. This RCT was divided into two substudies to
determine the CV safety of lumiracoxib (400 mg once daily;
n=4741) compared with naproxen (500 mg twice daily; n=4730)
and lumiracoxib (400 mg once daily; n=4376) compared with
ibuprofen (800 mg three times daily; n=4397) (Farkouh et al. 2004). 
Approximately 24% (n=4326) of patients participating in TARGET
were taking low-dose aspirin, although only 36% (n=1561) of
these were classified as high CV risk. The incidence of MI did not
differ significantly between lumiracoxib and either ibuprofen or
naproxen, irrespective of aspirin use. However, in the naproxen
substudy in patients not taking low-dose aspirin fewer patients
had MIs in the naproxen 500 mg twice-daily group (four events,
0.11%) compared with the lumiracoxib group (ten events, 0.28%)
(P=0.1454). The dose of lumiracoxib used in TARGET was four
times the current recommended dose of 100 mg for OA,
therefore, it may be expected that any CV risk would be reduced
at the indicated dose. 
In healthy subjects, lumiracoxib does not affect the ex-vivo
antiplatelet aggregation activity of low-dose aspirin (Jermany et
al. 2005). In contrast, naproxen inhibits platelet aggregation and
has been suggested to have an antithrombotic effect,
suppressing thromboxane production to a similar level as low-
dose aspirin (Capone et al. 2004). This property may explain the
reduced incidence of MI with naproxen compared with
lumiracoxib, although this remains debatable. Farkouh et al.
(2004) highlighted that the absence of a placebo arm in this 
study made it difficult to ascertain the real risk of MI with 
lumiracoxib alone.
Level 1 evidence from another meta analysis revealed no
significant difference in cerebrovascular event risk in patients
taking lumiracoxib compared with placebo, nonselective
NSAIDs, or other COX-2 inhibitors. A slightly higher risk was
found compared specifically with naproxen (OR 1.09, 95% CI
0.58, 2.04) and ibuprofen (OR 1.31, 95% CI 0.57, 2.98), although
this did not reach significance (Chen & Ashcroft 2006). The
authors concluded that any increase in CV risk with COX-2
inhibitors must therefore be mainly due to risk of MI.
A further meta analysis that included six lumiracoxib trials
revealed no effect on arrhythmia risk, although the authors stated
that the results were inconclusive due to the limited number of
studies (Zhang et al. 2006).
Lumiracoxib | clinical impact review
© 2007 Core Medical Publishing Limited 142
Table 9 | The risk of CV events with lumiracoxib in patients with
OA or RA: results from a meta analysis of all RCTs 
≥1 week and up to 1 year (Matchaba et al. 2005)
CV event RR (lumiracoxib vs
placebo)
RR (lumiracoxib
vs naproxen)
RR (lumiracoxib
vs nonnaproxen
NSAID
APTC 1.08
(15/7011 LX; 6/3234
PL)
1.49
(50/5964 LX;
31/5411
naproxen)
0.83
(22/6126 LX;
24/5058
nonnaproxen)
Myocardial
event
1.27
(6/7011 LX; 2/3234 PL)
1.69
(22/5964 LX;
12/5411
naproxen)
0.80
(7/6126 LX;
8/5058
nonnaproxen)
Stroke 0.59
(4/7011 LX; 3/3234 PL)
1.42
(20/5964 LX;
13/5411
naproxen)
0.91
(9/6126 LX;
9/5058
nonnaproxen)
APTC, Antiplatelet Trialists’ Collaboration composite CV endpoint of myocardial infarction,
stroke (ischemic and hemorrhagic), and CV death; CV, cardiovascular; LX, lumiracoxib;
NSAID, nonsteroidal antiinflammatory drug; PL, placebo; RCT, randomized controlled trial;
RR, relative risk.143
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Reference Duration of study
(wk)
Treatment (dose) Number of APTC events
(safety population)
Number of myocardial
events (safety population)
Number of stroke events
(safety population)
Berenbaum et al. 2005 1 LX (200/400 mg)
PL
0/204
0/103
RR: no events
0/204
0/103
RR: no events
0/204
0/103
RR: no events
Wittenberg et al. 2003 1 LX (400 mg)
PL
1/144
0/75
RR not estimable
1/144
0/75
RR not estimable
0/144
0/75
RR: no events
Benevolenskaya 
et al. 2003
4 LX (100 mg) 
PL
0/122
0/122
RR: no events
0/122
0/122
RR: no events
0/122
0/122
RR: no events
Grifka et al. 2004 4 LX (200/400 mg)
PL
0/398
0/196
RR: no events
0/398
0/196
RR: no events
0/398
0/196
RR: no events
Schnitzer et al. 2004a 4 LX (50/100/200/400 mg)
PL
Diclofenac (75 mg)
0/392
0/97
0/94
RR: no events 
0/392
0/97
0/94
RR: no events
0/392
0/97
0/94
RR: no events
Hawkey et al. 2003 6 LX (400 mg)
RX (25 mg)
NR NR NR
Fleischmann et al. 2005 13 LX (200/400 mg)
PL 
CX (200 mg)
2/925
0/231
NR 
RR not estimable
2/925
0/231
NR 
RR not estimable
0/925
0/231
NR
RR: no events
Tannenbaum et al. 2004 13 LX (200/400 mg)
PL
1/978
0/243
1/978
0/243
0/978
0/243
Novartis data on file
2002b
13 LX (400 mg)
PL
RX (25 mg)
1/205
2/204
NR
RR 0.46
0/205
1/204
NR
RR not estimable
0/205
1/204
NR
RR not estimable
Hawkey et al. 2004 13 LX (200/400 mg)
Ibuprofen (800 mg)
CX (200 mg)
1/524
1/260
NR
RR 0.46
1/524
1/260
NR
RR 0.46
0/524
0/260
NR
RR: no events
Sheldon et al. 2005 13 LX (100 mg)
PL
1/776
1/382
RR 0.43
0/776
0/382
RR: no events
0/776
1/382
RR not estimable
Lehmann et al. 2005 13 LX (100 mg)
PL2/840
1/424
RR 0.96
2/840
1/424
RR 0.96
0/840
1/424
RR not estimable
1/840
0/424
RR not estimable
Schell et al. 2003c 39 LX (100 mg)
LX (400 mg)
CX (200 mg)
NR NR NR
Pavelka et al. 2005
(abstract)
39 LX (100 mg)
CX (200 mg)
NR NR NR
Farkouh et al. 2004d 52 LX (400 mg)
Naproxen (500 mg)
LX (400 mg)
Ibuprofen (800 mg)
40/4741
27/4730
RR 1.44
19/4376
23/4397
RR 0.79
18/4741
10/4730
RR 1.75
5/4376
7/4397
RR 0.68
16/4741
12/4730
RR 1.30
8/4376
9/4397
RR 0.85
aThese data are not available in the primary references. Data for the incidence of CV events with the COX-2 comparators (celecoxib or rofecoxib) were not reported, therefore it is not provided
in this table.
bPublished as Berenbaum et al. 2005.
cExtension of Tannenbaum et al. 2004.
dTARGET study.
APTC, Antiplatelet Trialists’ Collaboration composite CV endpoint of myocardial infarction, stroke (ischemic and hemorrhagic), and CV death; COX-2, cyclooxygenase-2; CV, cardiovascular; 
CX, celecoxib; LX, lumiracoxib; NR, not reported; OA, osteoarthritis; PL, placebo; RR, relative risk; RCT, randomized controlled trial; RX, rofecoxib; TARGET, Therapeutic Arthritis Research and
Gastrointestinal Event Trial; wk, week.
Table 10 | Incidence and relative risk of CV events with lumiracoxib in patients with OA: results from a meta analysis of RCTs
(Matchaba et al. 2005)aLiver function 
Level 2 evidence from six RCTs in healthy volunteers (one study) and
patients with OA (five studies) showed that a small proportion of
patients receiving a high dose of lumiracoxib (400 mg) experienced
clinically relevant elevations in the liver function enzymes alanine
aminotransferase (ALT) and aspartate aminotransferase (AST),
which resolved on cessation of treatment (Table 11). These
elevations were greater than in patients receiving ibuprofen or
naproxen (Schnitzer et al. 2004b). However, at the indicated dose of
100 mg, the incidence was similar to that of celecoxib and placebo. 
There is some evidence that higher doses of lumiracoxib may be
associated with changes in liver function in some patients. Eleven
cases of severe hepatic adverse reactions, including nine cases of
liver failure, two deaths, and three liver transplants, at least possibly
related to lumiracoxib have been reported among the estimated 7
million patients who have been exposed to the drug since its launch
(MHRA 2007). Most of these reports were associated with doses of
200 to 400 mg/day. Nevertheless, there has been one report of a
transient liver reaction among the estimated 5400 patients receiving
the drug at 100 mg in the UK (MHRA 2007).
Renal function
The incidence of edema with lumiracoxib in five RCTs in patients
with OA is shown in Table 12. Results from these studies showed
that the incidence of edema with lumiracoxib did not appear to be
dose-related and was infrequent in the majority of studies (ranging
from 0% to 5%), with an incidence similar to that with celecoxib,
diclofenac, naproxen, and ibuprofen. The incidence was increased
in one RCT (11.5% for lumiracoxib 100 mg), but was also high for
placebo (4.1%) in this study.
Evidence from TARGET, in which 45% of patients had hypertension,
also showed that lumiracoxib 400 mg had a significantly less
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Reference Design and population Treatment (no.) Liver function outcomes
Rordorf et al. 2003 Healthy male volunteers
8 d, db, dd, RCT
200 mg LX bid (20)
PL (20)
500 mg naproxen bid (20)
ALT/AST elevations (fold increase over ULN ranged 
from 1.1 to 4.2 for AST and 1.1 to 2.2 for ALT): 4 pts LX, 
4 pts PL, 1 pt naproxen
Lehmann et al. 2005 Knee OA
13 wk, db, dd, mc, RCT
100 mg LX od (420)
100 mg LX od + 200 mg
loading dose LX od for first 2 wk (420)
200 mg CX od (420)
PL (424)
Incidence of liver function parameter elevations >3 x 
ULN: 0.2% 100 mg LX + loading dose, 0.5% PL, 0.2% CX
Sheldon et al. 2005 Knee OA
13 wk, db, dd, mc, RCT
100 mg LX od (391)
100 mg LX od + 200 mg 
loading dose LX od for first 2 wk (385)
200 mg CX od (393)
PL (382)
Incidence ALT/AST levels >3 x ULN: 0.3% for both 
LX and CX, 0% PL
Tannenbaum et al.
2004
Knee OA
13 wk, db, dd, mc, RCT
200 mg LX od (487)
400 mg LX od (491)
200 mg CX od (481)
PL (243)
Incidence ALT/AST levels >3 x ULN: 2 pts LX 
200 mg, 3 pts LX 400 mg, 4 pts CX. None were
accompanied by clinical symptoms
All cases resolved either while receiving study drug 
or after treatment had stopped. No clinical symptoms 
were associated with elevations
Fleischmann et al.
2005
Knee OA
13 wk, db, dd, mc, RCT
200 mg LX od (462)
400 mg LX od (463)
200 mg CX od (444)
PL (231)
Incidence ALT >3 x ULN: 0.4% 200 mg LX, 2.6% 
400 mg LX, 0.0% CX, 0.4% PL
Incidence AST >3 x ULN: 0.2% 200 mg LX, 1.1% 
400 mg LX, 0.2% CX, 0.4% PL
All cases resolved either while receiving study drug 
or after treatment had stopped. No clinical symptoms 
were associated with elevations
Schnitzer et al. 2004b Hip, knee, hand, or spine OA
52 wk, db, dd, mc, RCT
400 mg LX od (4376)
800 mg ibuprofen tid (4397)
400 mg LX od (4741)
500 mg naproxen bid (4730)
Proportion of pts with ALT/AST concentrations >3 x ULN was
greater with LX than with ibuprofen or naproxen [2.57%
(n=230) vs 0.63% (n=56) (HR 3.97)]
9 pts had probable or possible drug-induced clinical 
hepatitis: 6 events (0.07%) LX, 2 events (0.05%) ibuprofen, 
1 event (0.02%) naproxen
Abnormalities resolved on cessation of treatment. No cases of
liver failure, transplantation, or death attributable to drug-
induced hepatitis reported
ALT, alanine aminotransferase; AST, aspartate aminotransferase; bid, twice daily; CX, celecoxib; d, day; db, double-blind; dd, double-dummy; GI, gastrointestinal; HR, hazard ratio; 
LX, lumiracoxib; mc, multicenter; od, once daily; OA, osteoarthritis; PL, placebo; pts, patients; RCT, randomized controlled trial; tid, three times daily; ULN, upper limit of normal; wk, week.
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pronounced effect on systolic blood pressure (SBP) and diastolic
blood pressure (DBP) compared with the nonselective NSAIDs
(mean change from baseline SBP +0.4 mmHg vs +2.1 mmHg; DBP
–0.1 mmHg vs +0.5 mmHg; both P<0.0001). Farkouh et al. (2004)
suggested that this may be due to reduced sodium retention in
patients receiving lumiracoxib. 
Additional evidence from TARGET, published in abstract form,
showed that the incidence of de-novo hypertension with
lumiracoxib was low and similar to that with naproxen (Zacher et al.
2005; Table 13). The incidence of de-novo hypertension was
greater with ibuprofen compared with lumiracoxib. Therefore, it is
unlikely that the lower dose of lumiracoxib indicated for OA will
increase hypertension. These effects were seen in patients who
were also receiving concomitant aspirin. 
A subsequent meta analysis that included six lumiracoxib trials in
patients with OA or RA indicated no effect of the drug at a median
dosage of 300 mg/day on overall renal function (RR 1.07, 95% 
CI 0.68, 1.70), including peripheral edema (RR 1.31, 95% CI 0.75,
2.31), hypertension (RR 0.94, 95% CI 0.42, 2.12), or renal
dysfunction demonstrated by serum urea, creatinine, kidney disease
or renal failure (RR 0.75, 95% CI 0.17, 3.32) (Zhang et al. 2006).
Drug interactions
Lumiracoxib is metabolized by the cytochrome P450 isoform 
2C9 (CYP 2C9) (Mangold et al. 2004; Rordorf et al. 2005).
However, lumiracoxib has no significant pharmacokinetic
interactions with the CYP 2C9 substrate, warfarin (Bonner et al.
2003), or the CYP 2C9 inhibitor, fluconazole (Scott et al. 2004a).
Therefore, it is anticipated that lumiracoxib has a low potential 
for drug–drug interactions with other CYP 2C9 substrates.
Coadministration of lumiracoxib with common treatments for
dyspepsia (an aluminum hydroxide/magnesium hydroxide antacid
or omeprazole) has also been demonstrated to have no clinically
significant effect on the single-dose plasma pharmacokinetics 
of lumiracoxib (Scott et al. 2004b). In addition, moderate 
hepatic impairment and mild to moderate renal impairment do 
not appear to influence lumiracoxib exposure (Kalbag et al. 2004;
Rordorf et al. 2005).
Economic evidence and resource utilization
There is no published evidence of the cost effectiveness of
lumiracoxib. 
The acquisition cost of lumiracoxib in the UK is less than that of
celecoxib (net price 100 mg x 30 lumiracoxib £17.24 vs £21.55 for
celecoxib), and greater than that of nonselective NSAIDs, many of
which are in generic form (BNF 2005). 
Looking beyond acquisition cost, reducing the incidence 
(and subsequent management) of clinically significant ulcer
complications should have a beneficial effect on overall costs of
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Reference Design Treatment 
(no. patients)
Number (%) of
patients with
peripheral edema
Grifka 
et al. 2004
Hand OA 
4 wk, db, mc,
RCT 
200 mg LX od (205)
400 mg LX od (193)
PL (196)
1 (0.5)
0 (0.0)
0 (0.0)
Schnitzer 
et al. 2004a
Hip or knee OA
Phase II dose-
finding study
4 wk, db, RCT
50 mg LX bid (98)
100 mg LX bid (96)
200 mg LX bid (99)
400 mg LX od (99)
75 mg diclofenac 
bid (94)
PL (97)
5 (5.1)
11 (11.5)
8 (8.1)
8 (8.1)
5 (5.3)
4 (4.1)
Tannenbau
m et al.
2004
Knee OA
13 wk, db, dd,
mc RCT
200 mg LX od (487)
400 mg LX od (491)
200 mg CX od (481)
PL (243)
6 (1.2)
4 (0.8)
6 (1.2)
4 (1.6)
Fleischman
n et al. 2005
Knee OA
13 wk, db, dd,
mc RCT
200 mg LX od (462)
400 mg LX od (463)
200 mg CX od (444)
PL (231)
11 (2.4)
10 (2.2)
12 (2.7)
4 (1.7)
Zacher 
et al. 2005 
(abstract)
Hip, knee, hand,
or spine OA
52 wk, db, dd,
mc, RCT
400 mg LX od (4376)
800 mg ibuprofen tid
(4397)
400 mg LX od (4741)
500 mg naproxen bid
(4730)
Incidence in
nonaspirin
population: LX vs
ibuprofen/naproxen
(combined data)
4.6% vs 4.7%
Incidence in aspirin
population: LX vs
ibuprofen/naproxen
(combined data)
5.0% vs 5.5%
bid, twice daily; CX, celecoxib; db, double-blind; dd, double-dummy; LX, lumiracoxib; 
mc, multicenter; OA, osteoarthritis; od, once daily; PL, placebo; RCT, randomized
controlled trial; tid, three times daily; wk, week.
Table 12 | Level 2 evidence for the incidence of edema with
lumiracoxib treatment in patients with OA
Population Incidence of de-novo
hypertension (%)
Nonaspirin population
Lumiracoxib vs ibuprofen/naproxen 
(combined data)
5.0 vs 6.5 (P<0.01)
Lumiracoxib vs ibuprofen 5.0 vs 7.9 (P<0.01)
Lumiracoxib vs naproxen 5.0 vs 5.2
Aspirin population
Lumiracoxib vs ibuprofen/naproxen 
(combined data)
5.8 vs 6.5 (P=0.593)
Lumiracoxib vs ibuprofen 5.0 vs 7.2 (P=0.267)
Lumiracoxib vs naproxen 6.4 vs 6.1
OA, osteoarthritis
Table 13 | The incidence of de-novo hypertension with 
lumiracoxib treatment in patients with OA 
(level 2 evidence from TARGET; 
Zacher et al. 2005)managing OA. A cost-effectiveness and cost-utility analysis 
in patients at average risk of GI and CV events showed that 
an NSAID in combination with a PPI costs an incremental 
$US45 350 per additional ulcer complication avoided and 
$US309 666 per quality-adjusted life year (QALY) gained 
compared with an NSAID alone (Spiegel et al. 2005). A cost-
utility analysis for the long-term treatment of OA or RA has
suggested that the use of the first-generation COX-2 inhibitors
rofecoxib or celecoxib is only cost effective in patients with a
previous bleeding ulcer compared with the nonselective NSAID
naproxen (Spiegel et al. 2003). Cost comparisons of lumiracoxib
with nonselective NSAIDs (with or without gastroprotective
agents) in both patients at low and high risk of GI complications
are needed to determine whether the degree of risk reduction
offsets their increased cost. 
Clinical evidence demonstrates that lumiracoxib provided no
additional GI benefit compared with ibuprofen and naproxen in
patients receiving low-dose aspirin (75–100 mg/day) (Schnitzer
et al. 2004b). Therefore, lumiracoxib is not expected to be cost
effective in patients taking aspirin.
As detailed in the Current therapy options section, nonselective
NSAIDs and the COX-2 inhibitors rofecoxib and celecoxib have
been shown to increase BP. In patients with OA or RA, a 3
mmHg increase in SBP over 1 year was associated with a 4%
increase in the incidence of ischemic heart disease and stroke
events (Singh et al. 2003). A study estimating the clinical and
economic impact of a 2.26% increase in SBP in 7.3 million
American adults with OA and treated hypertension showed that
maintaining BP control would avoid >30 000 deaths from stroke
and 25 000 coronary deaths. This would theoretically result in
>449 000 person-years of life saved and $US1.4 billion in direct
healthcare cost savings (Grover et al. 2005). Limited clinical
evidence suggests that lumiracoxib does not increase the
incidence of de-novo hypertension, and that lumiracoxib did not
cause increased BP compared with patients receiving
nonselective NSAIDs. The cost benefit of this potential reduction
in CV events would be of interest. A clinical trial investigating the
effect of lumiracoxib 100 mg once daily compared with
ibuprofen 600 mg three times daily on ambulatory BP in patients
with OA and controlled hypertension is currently underway
(http://www.clinicaltrials.gov).
Patient group/population
Level 1 evidence from a Cochrane review of acetaminophen in 
OA concluded that the relative superiority of nonselective
NSAIDs over acetaminophen is most marked in patients 
with moderate to severe levels of pain (Towheed et al. 2006). 
As acetaminophen is inexpensive and well tolerated it is 
likely that it will continue to be used as an initial therapy option
for the initial treatment of patients with mild to moderate OA
pain. In patients who fail to achieve adequate symptomatic relief
with acetaminophen, nonselective NSAIDs are currently the
preferred option, with COX-2 inhibitors used as an alternative,
particularly in patients at high risk of developing serious GI
adverse effects.
Patients with CV risk factors
It is currently recommended that all NSAIDs, including COX-2
inhibitors, are used with caution in patients with risk factors for 
CV disease such as hypertension, hyperlipidemia, diabetes, and
smoking. However, a large proportion of patients with OA are likely
to be elderly, and have CV risk factors or established 
CV disease. 
The Third National Health And Nutrition Examination Survey
(NHANES III) reported that over 47% of US adults with OA were
older than 65 years of age and had a high prevalence of CV risk
factors (Singh et al. 2002). Approximately 40% of individuals aged
≥35 years with OA had hypertension, 20% smoked, 11% had
diabetes, and 32% had hypercholesterolemia. Therefore, a need
remains for a COX-2 inhibitor that can be used safely in this high-
risk population.
Data from TARGET demonstrate that lumiracoxib did not increase
the incidence of MI, stroke, or other thrombotic CV events in
patients that were treated for up to 1 year. This trial included
patients with CV risk factors; 45% were hypertensive, 8% had
diabetes, and 20% had dyslipidemia. Therefore,  lumiracoxib may
be used with caution in patients with these comorbidities (EMEA
2005b). However, patients with established CV disease were
excluded from TARGET. 
Low-dose aspirin has a cardioprotective (antiplatelet) effect due to
inhibition of the COX-1 enzyme. Therefore, it is prescribed to many
patients with CV disease. Data from TARGET show that in patients
receiving low-dose aspirin, lumiracoxib provided no benefit in ulcer
complication reduction over ibuprofen or naproxen. Topol and Falk
(2004) suggest that it is hard to justify the use of COX-2 inhibitors
in these patients. In addition, NICE guidelines suggest that
prescribing COX-2 inhibitors in combination with aspirin is not
justified as they would not provide a GI benefit (NICE 2001).
Patients with hepatic impairment
Patients treated with lumiracoxib 400 mg experienced reversible
elevations in liver function parameters. It is therefore likely that
there is a low potential for lumiracoxib at the indicated dosage of
100 mg to increase the incidence of liver dysfunction in the
outpatient setting. Liver function monitoring is advised before
starting and every month during lumiracoxib treatment (MHRA
2007). The drug is contraindicated in patients with, or at high risk
of, hepatic impairment (MHRA 2007).
Patients with renal impairment
NHANES III estimated that 37% of patients with OA have renal
impairment, but fewer than 1% experience renal failure. Clinical
evidence has shown that lumiracoxib is associated with a low
incidence of peripheral edema. The summary of product
characteristics states that under conditions of compromised renal
perfusion, administration of lumiracoxib may impair renal function
(EMEA 2005b). Therefore, it is recommended that monitoring of
renal function in these patients is considered.
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Dosage, administration, and formulations
In the EU, lumiracoxib is indicated for symptomatic relief of OA
at a recommended dose of 100 mg once daily. It is advised that
the patients’ need for symptomatic relief and response to
therapy is reevaluated periodically. The summary of product
characteristics advises that lumiracoxib is used with caution in
patients most at risk of developing a GI complication with
NSAIDs, and in patients with a history of cardiac failure, left
ventricular dysfunction, hypertension, or preexisting edema. It
warns that patients with significant CV risk factors should only
be treated with lumiracoxib after careful consideration.
Lumiracoxib is contraindicated in patients with current hepatic
disease, previous drug-induced elevations of alanine
aminotransferase (ALT)/aspartate aminotransferase (AST),
ALT/AST >1.5 x upper limit of normal (ULN) before treatment or
>3 x ULN during treatment, or taking other drugs that may
impair hepatic function (MHRA 2007).
Clinical value
Clear evidence indicates that lumiracoxib is as effective as the
nonselective NSAIDs diclofenac, naproxen, and ibuprofen, and
the COX-2 inhibitor celecoxib for the management of pain in
patients with OA, as shown by improvements in pain intensity
and joint stiffness. Evidence suggests that lumiracoxib
improves quality of life, as shown by improvements in WOMAC
scores for the ability to perform daily activities and
improvements in SF-36 scores for physical functioning and
mental health. However, the economic impact of lumiracoxib on
the treatment of OA, as compared to other currently available
medications, has not been reported. 
There is a need to identify the OA patient population most likely
to benefit from COX-2 inhibitors as an alternative to
nonselective NSAIDs. Evidence indicates that lumiracoxib is
associated with a lower risk of upper GI complications, which is
maintained for up to 1 year’s treatment, compared with
ibuprofen or naproxen. Patients already receiving aspirin would
not have a GI benefit from treatment with lumiracoxib because
of the inhibitory effects of aspirin on gastric COX-1. It is
expected that lumiracoxib will be included in updated
guidelines as an alternative therapy to nonselective NSAIDs in
combination with PPIs, and as an alternative primary therapy to
celecoxib in patients at high-risk of developing serious GI
adverse effects. The impact of lumiracoxib on hospitalization
and death rates resulting from GI complications compared to
other NSAIDs has not been reported. Given the higher
acquisition costs of lumiracoxib compared with nonselective
NSAIDs, many of which are available generically, these data are
important to evaluate any potential cost benefits.
There is moderate evidence that a high dose of lumiracoxib 
(400 mg) has a similar risk of CV events as ibuprofen and
naproxen over a 1-year period. Further evidence will confirm if
the CV safety is sustained in the longer term with approved
doses (100 mg). The impact of lumiracoxib on CV events
relative to other COX-2 inhibitors has not been reported. More
evidence is required to determine whether lumiracoxib has an
advantage over other COX-2 inhibitors with regard to CV risk
profile. In addition, the impact of lumiracoxib on CV events in
patients with CV disease has not been reported. As the majority
of patients with OA are aged ≥65 years, often have CV risk
factors, and receive aspirin medication, more evidence
evaluating the expected role of lumiracoxib in the management
of these patients is needed. 
The potential for adverse hepatic effects with lumiracoxib limit
its usefulness. The drug was withdrawn from Australia in
August 2007 following reports of serious adverse liver reactions
(Therapeutic Goods Administration 2007), although this was at
doses greater than the 100 mg approved in the EU. However,
two cases of adverse liver reactions at this dose resulted in the
drug being withdrawn in Canada in October 2007 (Health
Canada 2007), and the drug has not been approved by the FDA
because of concerns over its potential to impair liver function
(Anon. 2007). In the EU, the drug is contraindicated in patients
with current, or at risk from, hepatic dysfunction (MHRA 2007).
The risk of adverse liver reactions appears to be small, with 11
case reports of severe reactions in the estimated 7 million
patients who have taken the drug since it was introduced
(MHRA 2007). Furthermore, the safety data reviewed by the
FDA revealed that 0.85% of patients receiving lumiracoxib 100
mg for 12 months had ALT and AST elevations >3 x ULN, a rate
considered to be similar to that seen with other NSAIDs 
(Anon. 2007).
In summary, lumiracoxib is a new COX-2 inhibitor providing 
an alternative treatment option for the management of OA, 
with comparable efficacy and CV safety to nonselective
NSAIDs, but with a lower risk of GI complications in 
patients not taking aspirin. It may provide an acceptable
risk–benefit balance in patients with a higher incidence of 
GI complications, including those with ulcers or being treated
with anticoagulants.
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